Olanzapine is superior to lamotrigine in the prevention of bipolar depression: a naturalistic observational study

Pei-Yin Pan, Meei-Shyuan Lee, Miao-Chi Lo, En-Lin Yang, Chin-Bin Yeh, Pei-Yin Pan, Meei-Shyuan Lee, Miao-Chi Lo, En-Lin Yang, Chin-Bin Yeh

Abstract

Background: Bipolar disorder is a highly recurrent disease and has great impact on the function of patients. Depressive symptoms consist of more than 50% of life time during the illness and may lead to self harm or suicidal behaviors. Little is known about the antidepressant effects of olanzapine, an atypical antipsychotic, as monotherapy despite its indication for preventing manic episodes. In contrast, lamotrigine, a mood stabilizer, has been proven to be effective in preventing depression in patients with bipolar disorder. However, no studies have compared the efficacy between lamotrigine and olanzapine in the maintenance treatment of bipolar disorder. This enriched naturalistic study was implemented to assess the effectiveness of olanzapine and lamotrigine as monotherapy in the prevention of recurrence of bipolar disorder.

Methods: Patients with bipolar disorder in a euthymic state (Young's Mania Rating Scale (YMRS) score <12, and 21-item Hamilton Depression Rating Scale (HAM-D) score <7) for at least two months, having already received either olanzapine or lamotrigine as the maintenance treatment were recruited. The patients maintained with olanzapine (n = 22) were applied to olanzapine group whereas those maintained with lamotrigine (n = 29) were applied to lamotrigine group. They were followed up for 12 months. Differences in the efficacy between olanzapine and lamotrigine in recurrence prevention were analyzed. The Kaplan-Meier method was used to generate time-to-recurrence curves, and differences between the two groups were compared using the log-rank test.

Results: Olanzapine had a significantly lower recurrence rate of depressive episodes than lamotrigine (20.0% vs. 57.7%, χ2 = 6.62, p = .010). However, olanzapine and lamotrigine had similar mania (15.0% vs. 0%, χ2 = 4.17, p = .075, Fisher's exact test) and any mood episode (35.0% vs. 57.7%, χ2 = 2.33, p = .127) recurrence rates. Olanzapine was significantly superior to lamotrigine in the time to recurrence of depressive episodes (χ2 = 4.55, df = 1, p = .033), but there was no difference in the time to recurrence of any mood episode (χ2 = 1.68, df = 1, p = .195).

Conclusions: This prospective naturalistic study suggests that olanzapine is more effective than lamotrigine in the prevention of depressive episodes in patients with bipolar disorder. Future large-scale randomized studies are warranted to validate our results.

Trial registration: ClinicalTrials.gov ID NCT01864551.

Figures

Figure 1
Figure 1
Patient disposition during the study.
Figure 2
Figure 2
Time to recurrence into depressive episode: Kaplan-Meier survival curves. The olanzapine group had a significantly longer time to recurrence into depressive episode than the lamotrigine group (χ2 = 4.55, df = 1, p = .033, log-rank test).
Figure 3
Figure 3
Time to recurrence into any mood episode: Kaplan-Meier survival curves. The olanzapine group did not differ from the lamotrigine group in time to recurrence to any mood episode (χ2 = 1.68, df = 1, p = .195, log-rank test).

References

    1. Tohen M, Waternaux CM, Tsuang MT. Outcome in Mania. A 4-year prospective follow-up of 75 patients utilizing survival analysis. Arch Gen Psychiatry. 1990;47(12):1106–11. doi: 10.1001/archpsyc.1990.01810240026005.
    1. Coryell W, Keller M, Endicott J, Andreasen N, Clayton P, Hirschfeld R. Bipolar II illness: course and outcome over a five-year period. Psychol med. 1989;19(1):129–41. doi: 10.1017/S0033291700011090.
    1. Gitlin MJ, Swendsen J, Heller TL, Hammen C. Relapse and impairment in bipolar disorder. Am J Psychiatry. 1995;152(11):1635–40.
    1. Keller MB, Lavori PW, Coryell W, Endicott J, Mueller TI. Bipolar I: a five-year prospective follow-up. J Nerv Ment Dis. 1993;181(4):238–45. doi: 10.1097/00005053-199304000-00005.
    1. Tohen M, Zarate CA Jr, Hennen J, Khalsa HM, Strakowski SM, Gebre-Medhin P, Salvatore P, Baldessarini RJ. The McLean-Harvard first-episode mania study: prediction of recovery and first recurrence. Am J Psychiatry. 2003;160(12):2099–107. doi: 10.1176/appi.ajp.160.12.2099.
    1. Judd LL, Akiskal HS. Depressive episodes and symptoms dominate the longitudinal course of bipolar disorder. Curr Psychiatry Rep. 2003;5(6):417–8. doi: 10.1007/s11920-003-0077-2.
    1. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Leon AC, Solomon DA, Coryell W, Maser JD, Keller MB. Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch Gen Psychiatry. 2005;62(12):1322–30. doi: 10.1001/archpsyc.62.12.1322.
    1. Simpson SG, Jamison KR. The risk of suicide in patients with bipolar disorders. J Clin Psychiatry. 1999;60(Suppl 2):53–6.
    1. McElroy SL, Altshuler LL, Suppes T, Keck PE Jr, Frye MA, Denicoff KD, Nolen WA, Kupka RW, Leverich GS, Rochussen JR, Rush AJ, Post RM. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am J Psychiatry. 2001;158(3):420–6. doi: 10.1176/appi.ajp.158.3.420.
    1. Brieger P, Ehrt U, Marneros A. Frequency of comorbid personality disorders in bipolar and unipolar affective disorders. Compr Psychiatry. 2003;44(1):28–34. doi: 10.1053/comp.2003.50009.
    1. Perlis RH, Ostacher MJ, Patel JK, Marangell LB, Zhang H, Wisniewski SR, Ketter TA, Miklowitz DJ, Otto MW, Gyulai L, Reilly-Harrington NA, Nierenberg AA, Sachs GS, Thase ME. Predictors of recurrence in bipolar disorder: primary outcomes from the systematic treatment enhancement program for bipolar disorder (STEP-BD) Am J Psychiatry. 2006;163(2):217–24. doi: 10.1176/appi.ajp.163.2.217.
    1. Cusin C, Serretti A, Lattuada E, Mandelli L, Smeraldi E. Impact of clinical variables on illness time course in mood disorders. Psychiatry Res. 2000;97(2–3):217–27.
    1. Kessing LV, Andersen PK, Mortensen PB, Bolwig TG. Recurrence in affective disorder. I. Case register study. Br J Psychiatry. 1998;172:23–8. doi: 10.1192/bjp.172.1.23.
    1. Wenze SJ, Gaudiano BA, Weinstock LM, Miller IW. Personality pathology predicts outcomes in a treatment-seeking sample with bipolar I disorder. Depress Res Treat. 2014;2014:816524.
    1. Bieling PJ, MacQueen GM, Marriot MJ, Robb JC, Begin H, Joffe RT, Young LT. Longitudinal outcome in patients with bipolar disorder assessed by life-charting is influenced by DSM-IV personality disorder symptoms. Bipolar Disord. 2003;5(1):14–21. doi: 10.1034/j.1399-5618.2003.00014.x.
    1. Vieta E, Suppes T. Bipolar II disorder: arguments for and against a distinct diagnostic entity. Bipolar Disord. 2008;10(1 Pt 2):163–78.
    1. Skeppar P, Adolfsson R. Bipolar II and the bipolar spectrum. Nord J Psychiatry. 2006;60(1):7–26. doi: 10.1080/08039480500504685.
    1. Fountoulakis KN, Kontis D, Gonda X, Yatham LN. A systematic review of the evidence on the treatment of rapid cycling bipolar disorder. Bipolar disord. 2013;15(2):115–37. doi: 10.1111/bdi.12045.
    1. Nivoli AM, Pacchiarotti I, Rosa AR, Popovic D, Murru A, Valenti M, Bonnin CM, Grande I, Sanchez-Moreno J, Vieta E, Colom F. Gender differences in a cohort study of 604 bipolar patients: the role of predominant polarity. J Affect Disord. 2011;133(3):443–9. doi: 10.1016/j.jad.2011.04.055.
    1. Altshuler LL, Kupka RW, Hellemann G, Frye MA, Sugar CA, McElroy SL, Nolen WA, Grunze H, Leverich GS, Keck PE, Zermeno M, Post RM, Suppes T. Gender and depressive symptoms in 711 patients with bipolar disorder evaluated prospectively in the Stanley foundation bipolar treatment outcome network. Am J Psychiatry. 2010;167(6):708–15. doi: 10.1176/appi.ajp.2009.09010105.
    1. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, O'Donovan C, Macqueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Milev R, Bond DJ, Frey BN, Goldstein BI, Lafer B, Birmaher B, Ha K, Nolen WA, Berk M. Canadian network for mood and anxiety treatments (CANMAT) and international society for bipolar disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15(1):1–44. doi: 10.1111/bdi.12025.
    1. Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study) J Clin Psychiatry. 2011;72(11):1452–64. doi: 10.4088/JCP.11m06878.
    1. Suppes T, Vieta E, Liu S, Brecher M, Paulsson B. Maintenance treatment for patients with bipolar I disorder: results from a north American study of quetiapine in combination with lithium or divalproex (trial 127) Am J Psychiatry. 2009;166(4):476–88. doi: 10.1176/appi.ajp.2008.08020189.
    1. Vieta E, Suppes T, Eggens I, Persson I, Paulsson B, Brecher M. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126) J Affect Disord. 2008;109(3):251–63. doi: 10.1016/j.jad.2008.06.001.
    1. Tohen M, Calabrese JR, Sachs GS, Banov MD, Detke HC, Risser R, Baker RW, Chou JC, Bowden CL. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry. 2006;163(2):247–56. doi: 10.1176/appi.ajp.163.2.247.
    1. Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, Purgato M, Spineli LM, Goodwin GM, Geddes JR. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet. 2011;378(9799):1306–15. doi: 10.1016/S0140-6736(11)60873-8.
    1. Tohen M, Calabrese J, Vieta E, Bowden C, Gonzalez-Pinto A, Lin D, Xu W, Corya S. Effect of comorbid anxiety on treatment response in bipolar depression. J Affect Disord. 2007;104(1–3):137–46.
    1. Maina G, Albert U, Rosso G, Bogetto F. Olanzapine or lamotrigine addition to lithium in remitted bipolar disorder patients with anxiety disorder comorbidity: a randomized, single-blind, pilot study. J Clin Psychiatry. 2008;69(4):609–16. doi: 10.4088/JCP.v69n0413.
    1. Gaudiano BA, Miller IW. Anxiety disorder comobidity in Bipolar I Disorder: relationship to depression severity and treatment outcome. Depress Anxiety. 2005;21(2):71–7. doi: 10.1002/da.20053.
    1. Otto MW, Simon NM, Wisniewski SR, Miklowitz DJ, Kogan JN, Reilly-Harrington NA, Frank E, Nierenberg AA, Marangell LB, Sagduyu K, Weiss RD, Miyahara S, Thas ME, Sachs GS. Pollack MH; STEP-BD Investigators. Prospective 12-month course of bipolar disorder in out-patients with and without comorbid anxiety disorders. Br J Psychiatry. 2006;189:20–5. doi: 10.1192/bjp.bp.104.007773.
    1. Feske U, Frank E, Mallinger AG, Houck PR, Fagiolini A, Shear MK, Grochocinski VJ, Kupfer DJ. Anxiety as a correlate of response to the acute treatment of bipolar I disorder. Am J Psychiatry. 2000;157(6):956–62. doi: 10.1176/appi.ajp.157.6.956.
    1. Tohen M, Ketter TA, Zarate CA, Suppes T, Frye M, Altshuler L, Zajecka J, Schuh LM, Risser RC, Brown E, Baker RW. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry. 2003;160(7):1263–71. doi: 10.1176/appi.ajp.160.7.1263.
    1. Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, Koukopoulos A, Cassano GB, Grunze H, Licht RW, Dell'Osso L, Evans AR, Risser R, Baker RW, Crane H, Dossenbach MR, Bowden CL. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry. 2005;162(7):1281–90. doi: 10.1176/appi.ajp.162.7.1281.
    1. Trankner A, Sander C, Schonknecht P. A critical review of the recent literature and selected therapy guidelines since 2006 on the use of lamotrigine in bipolar disorder. Neuropsychiatr Dis Treat. 2013;9:101–11.
    1. Seo HJ, Chiesa A, Lee SJ, Patkar AA, Han C, Masand PS, Serretti A, Pae CU. Safety and tolerability of lamotrigine: results from 12 placebo-controlled clinical trials and clinical implications. Clin Neuropharmacol. 2011;34(1):39–47. doi: 10.1097/WNF.0b013e3182055c07.
    1. Baldessarini R, Henk H, Sklar A, Chang J, Leahy L. Psychotropic medications for patients with bipolar disorder in the United State: polytherapy and adherence. Psychiatr Serv. 2008;59(10):1175–83. doi: 10.1176/appi.ps.59.10.1175.
    1. Bowden CL, Calabrese JR, Sachs G, Yatham LN, Asghar SA, Hompland M, Montgomery P, Earl N, Smoot TM, DeVeaugh-Geiss J. Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003;60(4):392–400. doi: 10.1001/archpsyc.60.4.392.
    1. Calabrese JR, Bowden CL, Sachs G, Yatham LN, Behnke K, Mehtonen OP, Montgomery P, Ascher J, Paska W, Earl N, DeVeaugh-Geiss J. Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry. 2003;64(9):1013–24. doi: 10.4088/JCP.v64n0906.
    1. Licht RW, Nielsen JN, Gram LF, Vestergaard P, Bendz H. Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6) Bipolar Disord. 2010;12(5):483–93. doi: 10.1111/j.1399-5618.2010.00836.x.
    1. Brown E, Dunner DL, McElroy SL, Keck PE, Adams DH, Degenhardt E, Tohen M, Houston JP. Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression. Int J Neuropsychopharmacol. 2009;12(6):773–82. doi: 10.1017/S1461145708009735.
    1. Tschoner A, Engl J, Laimer M, Kaser S, Rettenbacher M, Fleischhacker WW, Patsch JR, Ebenbichler CF. Metabolic side effects of antipsychotic medication. Int J Clin Pract. 2007;61(8):1356–70. doi: 10.1111/j.1742-1241.2007.01416.x.
    1. Ghaemi SN, Hsu DJ, Thase ME, Wisniewski SR, Nierenberg AA, Miyahara S, Sachs G. Pharmacological treatment patterns at study entry for the first 500 STEP-BD participants. Psychiatr Serv. 2006;57(5):660–5. doi: 10.1176/appi.ps.57.5.660.
    1. Saaiq M, Iqbal T. Report: Fatal toxic epidermal necrolysis induced by sodium valproate. Pak J Pharm Sci. 2013;26(3):637–9.
    1. Arsenovic N, Sheehan L, Clark D, Moreira R. Fatal carbamazepine induced fulminant eosinophilic (hypersensitivity) myocarditis: emphasis on anatomical and histological characteristics, mechanisms and genetics of drug hypersensitivity and differential diagnosis. J Forensic Leg Med. 2010;17(2):57–61. doi: 10.1016/j.jflm.2009.07.021.
    1. Tamayo JM, Sutton VK, Mattei MA, Diaz B, Jamal HH, Vieta E, Zarate CA Jr, Fumero I, Tohen M. Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: an open-label, randomized, flexible-dose study in Puerto Rico. J Clin Psychopharmacol. 2009;29(4):358–61. doi: 10.1097/JCP.0b013e3181ad223f.
    1. Cipriani A, Rendell J, Geddes JR. Olanzapine in the long-term treatment of bipolar disorder: a systematic review and meta-analysis. J Psychopharmacol. 2010;24(12):1729–38. doi: 10.1177/0269881109106900.
    1. Altamura AC, Russo M, Vismara S, Mundo E. Comparative evaluation of olanzapine efficacy in the maintenance treatment of bipolar disorder. J Clin Psychopharmacol. 2004;24(4):454–6. doi: 10.1097/01.jcp.0000132344.35713.5f.
    1. Tohen M, Chengappa KN, Suppes T, Baker RW, Zarate CA, Bowden CL, Sachs GS, Kupfer DJ, Ghaemi SN, Feldman PD, Risser RC, Evans AR, Calabrese JR. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry. 2004;184:337–45. doi: 10.1192/bjp.184.4.337.
    1. Sylvia LG, Dupuy JM, Ostacher MJ, Cowperthwait CM, Hay AC, Sachs GS, Nierenberg AA, Perlis RH. Sleep disturbance in euthymic bipolar patients. J Psychopharmacol. 2012;26(8):1108–12. doi: 10.1177/0269881111421973.
    1. Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, Pope HG Jr, Chou JC, Keck PE Jr, Rhodes LJ, Swann AC, Hirschfeld RM, Wozniak PJ. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry. 2000;57(5):481–9. doi: 10.1001/archpsyc.57.5.481.
    1. Vieta E, Gunther O, Locklear J, Ekman M, Miltenburger C, Chatterton ML, Astrom M, Paulsson B. Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol. 2011;14(8):1029–49. doi: 10.1017/S1461145711000885.
    1. Gitlin M, Frye MA. Maintenance therapies in bipolar disorders. Bipolar Disord. 2012;14(Suppl 2):51–65.
    1. Johnson FR, Ozdemir S, Manjunath R, Hauber AB, Burch SP, Thompson TR. Factors that affect adherence to bipolar disorder treatments: a stated-preference approach. Med Care. 2007;45(6):545–52. doi: 10.1097/MLR.0b013e318040ad90.
    1. Chien IC, Chang KC, Lin CH, Chou YJ, Chou P. Prevalence of diabetes in patients with bipolar disorder in Taiwan: a population-based national health insurance study. Gen Hosp Psychiatry. 2010;32(6):577–82. doi: 10.1016/j.genhosppsych.2010.09.005.
    1. van der Loos ML, Mulder P, Hartong EG, Blom MB, Vergouwen AC, van Noorden MS, Timmermans MA, Vieta E, Nolen WA, LamLit Study G. Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design. Bipolar Disord. 2011;13(1):111–7. doi: 10.1111/j.1399-5618.2011.00887.x.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren